Psoriatic arthritis is chronic condition in which joint inflammation (arthritis) is associated with a skin condition that involves red, often thickened, flaky patches of skin (called psoriasis). It can start at any age, with the psoriasis typically developing before the development of psoriatic arthritis.
The Mount Sinai Department of Dermatology offers uniquely specialized care in the treatment of psoriatic arthritis. Known worldwide for our expertise in psoriasis research and treatment, Mount Sinai is conducting innovative clinical trials in psoriatic arthritis, giving our patients access to cutting-edge treatments not available elsewhere. We are also the only institution in New York State with physicians who are board certified in both rheumatology and dermatology. Our entire team is skilled in drawing on the newest science to personalize a safe and effective treatment plan for each patient.
Causes of Psoriatic Arthritis
The exact causes of psoriatic arthritis are not yet understood. It is believed that genetic and environmental factors may be involved. Your risk for psoriatic arthritis appears to increase if you already have a widespread, severe case of psoriasis.
Symptoms of Psoriatic Arthritis
Psoriatic arthritis symptoms may develop quickly or gradually and range from mild to severe. These symptoms include:
- Swelling and tenderness near the tendons called enthesitis
- Swelling in toes and fingers called dactylitis or sausage digits
- Pain, stiffness, and swelling in one or several joints
- Reduced range of motion
Treatments for Psoriatic Arthritis
Mount Sinai’s Department of Dermatology is a world leader in innovative research and innovative treatments for psoriatic arthritis, offering patients access to promising new treatments beyond what is available at other institutions. We take a collaborative approach, with specialists who are board certified in rheumatology and dermatology working closely with other disciplines to provide comprehensive care.
Because untreated Psoriatic arthritis could result in permanent joint damage, our team is committed to prompt diagnosis and early treatment.
In addition to clinical trials, we provide the full range of treatments for psoriatic arthritis, including the following:
- Disease-modifying antirheumatic drugs (DMARDs): These include methotrexate, leflunomide, and sulfasalazine.
- Biologic medications: These medicines treat both the skin and joint disease by blocking different protein molecules